SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Badman MK, Flier JS. The gut and energy balance: visceral allies in the obesity wars. Science 2005; 307: 19091914.
  • 2
    Schwartz MW. Central nervous system regulation of food intake. Obesity (Silver Spring) 2006; 14 Suppl 1: 1S8S.
  • 3
    Roth JD, Mack C, Parkes DG, Kesty NC, Weyer C. Integrated neurohormonal approaches to the treatment of obesity: the amylin agonist pramlintide and its interactions with leptin and PYY signaling pathways. In: Bray GA, Bouchard C (eds). Handbook of Obesity Clinical Applications. Informa Healthcare USA, Inc.: New York City, NY, 2008, pp 341361.
  • 4
    Chen HC, Roth JD, Schroeder BE, Weyer C. Role of islet-, gut-, and adipocyte-derived hormones in the central control of food intake and body weight: implications for an integrated neurohormonal approach to obesity pharmacotherapy. Curr Diabetes Rev 2008; 4: 7991.
  • 5
    Farooqi IS, Jebb SA, Langmack G et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 1999; 341: 879884.
  • 6
    Farooqi IS, Matarese G, Lord GM et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002; 110: 10931103.
  • 7
    Montague CT, Farooqi IS, Whitehead JP et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997; 387: 903908.
  • 8
    Heymsfield SB, Greenberg AS, Fujioka K et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 1999; 282: 15681575.
  • 9
    Lutz TA. Pancreatic amylin as a centrally acting satiating hormone. Curr Drug Targets 2005; 6: 181189.
  • 10
    Lutz TA. Amylinergic control of food intake. Physiol Behav 2006; 89: 465471.
  • 11
    Smith SR, Blundell JE, Burns C et al. Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study. Am J Physiol Endocrinol Metab 2007; 293: E620E627.
  • 12
    Aronne L, Fujioka K, Aroda V et al. Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Metab 2007; 92: 29772983.
  • 13
    Smith SR, Aronne LJ, Burns CM et al. Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care 2008; 31: 18161823.
  • 14
    Rosenbaum M, Vandenborne K, Goldsmith R et al. Effects of experimental weight perturbation on skeletal muscle work efficiency in human subjects. Am J Physiol Regul Integr Comp Physiol 2003; 285: R183R192.
  • 15
    Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. N Engl J Med 1995; 332: 621628.
  • 16
    Rosenbaum M, Goldsmith R, Bloomfield D et al. Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. J Clin Invest 2005; 115: 35793586.
  • 17
    Rosenbaum M, Murphy EM, Heymsfield SB, Matthews DE, Leibel RL. Low dose leptin administration reverses effects of sustained weight-reduction on energy expenditure and circulating concentrations of thyroid hormones. J Clin Endocrinol Metab 2002; 87: 23912394.
  • 18
    Kissileff HR, Thornton JC, Torres M et al. Maintenance of reduced body weight in humans is associated with leptin-reversible changes in appetite-related ratings [abstract]. Presented at the Society for Neuroscience Annual Meeting, 3–7 November 2007, San Diego, California.
  • 19
    Morton GJ, Blevins JE, Williams DL et al. Leptin action in the forebrain regulates the hindbrain response to satiety signals. J Clin Invest 2005; 115: 703710.
  • 20
    Morton GJ, Matsen M, Figlewicz D, Schwartz MW. Leptin signaling in the ventral tegmental area enhances the satiety response to cholecystokinin. Diabetes 2007; 56: A403.
  • 21
    Roth JD, Roland BL, Cole RL et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci USA 2008; 105: 72577262.
  • 22
    Trevaskis JL, Coffey T, Cole R et al. Amylin-mediated restoration of leptin responsiveness in diet-induced obesity: magnitude and mechanisms. Endocrinology 2008; 149: 56795687.
  • 23
    Frankenfield DC, Rowe WA, Smith JS, Cooney RN. Validation of several established equations for resting metabolic rate in obese and nonobese people. J Am Diet Assoc 2003; 103: 11521159.
  • 24
    Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361370.
  • 25
    Cummings DE, Overduin J. Gastrointestinal regulation of food intake. J Clin Invest 2007; 117: 1323.
  • 26
    Hukshorn CJ, Saris WH, Westerterp-Plantenga MS et al. Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men. J Clin Endocrinol Metab 2000; 85: 40034009.
  • 27
    Bray GA, Greenway FL. Pharmacological treatment of the overweight patient. Pharmacol Rev 2007; 59: 151184.
  • 28
    Oral EA, Simha V, Ruiz E et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med 2002; 346: 570578.
  • 29
    Ebihara K, Kusakabe T, Hirata M et al. Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. J Clin Endocrinol Metab 2007; 92: 532541.
  • 30
    Javor ED, Cochran EK, Musso C et al. Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. Diabetes 2005; 54: 19942002.
  • 31
    Chapman I, Parker B, Doran S et al. Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia 2005; 48: 838848.
  • 32
    Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 16961705.
  • 33
    Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 2006; 355: 704712.